Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Treatment of Cancer Lung Cancer Group"'
Autor:
Giaj-Levra, Niccolò, Giaj-Levra, Matteo, Durieux, Valerie, Novello, Silvia, Besse, Benjamin, Hasan, Baktiar, Hendriks, Lizza E., Levy, Antonin, Dingemans, Anne-Marie C., Berghmans, Thierry, European Organization for Research and Treatment of Cancer-Lung Cancer Group
Publikováno v:
Journal of Thoracic Oncology; Dec2019, Vol. 14 Issue 12, p2053-2061, 9p
Autor:
Scagliotti, Giorgio Vittorio, Smit, E, Bosquee, L, O'Brien, M, Ardizzoni, A, Zatloukal, P, Eberhardt, W, Smid Geirnaerdt, M, de Bruin HG, Dussenne, S, Legrand, C, Giaccone, G, European Organisation for Research, Treatment of Cancer Lung Cancer Group
Publikováno v:
Lung Cancer, 50(1), 91-96. Elsevier Ireland Ltd
Scagliotti, GV, Smit, E F, Bosquee, L, O'Brien, M, Ardizzoni, A, Zatloukal, P, Eberhardt, W, Smid-Geirnaerdt, M, de Bruin, H G, Dussenne, S, Legrand, C & Giaccone, G 2005, ' A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956) ', Lung Cancer, vol. 50, no. 1, pp. 91-96 . https://doi.org/10.1016/j.lungcan.2005.05.012
Scagliotti, GV, Smit, E F, Bosquee, L, O'Brien, M, Ardizzoni, A, Zatloukal, P, Eberhardt, W, Smid-Geirnaerdt, M, de Bruin, H G, Dussenne, S, Legrand, C & Giaccone, G 2005, ' A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956) ', Lung Cancer, vol. 50, no. 1, pp. 91-96 . https://doi.org/10.1016/j.lungcan.2005.05.012
Purpose: The incidence of bronchioloalveolar carcinoma (BAC) has risen steadily over the last decades along with the increasing frequency of adenocarcinomas. BAC is relatively resistant to commonly used chemotherapy regimens. A phase 11 study with si
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ea65d55a2b4b205b3edea567440899b
https://doi.org/10.1016/j.lungcan.2005.05.012
https://doi.org/10.1016/j.lungcan.2005.05.012
Autor:
Franz M.N.H. Schramel, C. Debruyne, Vivianne C. G. Tjan-Heijnen, Catherine Legrand, Nico van Zandwijk, Egbert F. Smit, Gijs W. P. M. Kramer, Jan P. van Meerbeeck, Paul Van Schil, Giuseppe Giaccone, Ted A.W. Splinter, Bonne Biesma
Publikováno v:
Journal of the National Cancer Institute
Journal of the National Cancer Institute, 99, 6, pp. 442-50
Journal of the National Cancer Institute, Vol. 99, no.6, p. 442-450 (March 2007)
Journal of the National Cancer Institute, 99, 442-50
Journal of the National Cancer Institute, 99, 6, pp. 442-50
Journal of the National Cancer Institute, Vol. 99, no.6, p. 442-450 (March 2007)
Journal of the National Cancer Institute, 99, 442-50
Contains fulltext : 52756tjan-heijnen.pdf (Publisher’s version ) (Closed access) BACKGROUND: Induction chemotherapy before surgical resection increases survival compared with surgical resection alone in patients with stage IIIA-N2 non-small-cell lu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f95f4512b37b3472f6fcc92b743d933
https://hdl.handle.net/10067/634320151162165141
https://hdl.handle.net/10067/634320151162165141
Autor:
V.C. Tjan-Heijnen, M. Mollers, E. Buchholz, G. Giaccone, Pieter E. Postmus, Christian Manegold, C. Debruyne, Catherine Legrand, Andrea Ardizzoni, Steven Gans, J. Van Meerbeeck, J.T.M. Burghouts, Bonne Biesma
Publikováno v:
Annals of Oncology, 12, 10, pp. 1359-68
Annals of Oncology, 12, 1359-68
Annals of oncology
Annals of Oncology, 12, 1359-68
Annals of oncology
Item does not contain fulltext BACKGROUND: CDE (cyclophosphamide, doxorubicin, etoposide) is one of the standard chemotherapy regimens in the treatment of small-cell lung cancer (SCLC), with myelosuppression as dose-limiting toxicity. In this trial t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c728d6abd42b6140d91b9906e7041126
https://hdl.handle.net/2066/186897
https://hdl.handle.net/2066/186897
Autor:
Giaj-Levra N; Department of Advanced Radiation Oncology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Italy; Young Investigators European Organization for Research and Treatment of Cancer Lung Cancer Group, Brussels, Belgium. Electronic address: niccolo.giajlevra@sacrocuore.it., Giaj Levra M; Young Investigators European Organization for Research and Treatment of Cancer Lung Cancer Group, Brussels, Belgium; Respiratory Oncology Unit, Department of Thoracic and Vascular Disease, CHU Grenoble Alpes, Grenoble, France., Berghmans T; Department of Intensive Care and Oncological Emergencies and Thoracic Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium., Novello S; Oncology Department, University of Turin, AOU San Luigi, Orbassano, Italy., Hendriks LE; Young Investigators European Organization for Research and Treatment of Cancer Lung Cancer Group, Brussels, Belgium; Department of Pulmonary Diseases, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, the Netherlands., Levy A; Young Investigators European Organization for Research and Treatment of Cancer Lung Cancer Group, Brussels, Belgium; Department of Radiation Oncology, Gustave Roussy, Institut d'Oncologie Thoracique, INSERM U1030, Université Paris-Saclay, F-94805, Villejuif, France., Besse B; Department of Cancer Medicine, Gustave Roussy, Institut d'Oncologie Thoracique, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France., Dingemans AC; Department of Pulmonary Diseases, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, the Netherlands; Department of Pulmonary Diseases, Erasmus Medical Center, Rotterdam, the Netherlands.
Publikováno v:
Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2020 Jan; Vol. 139, pp. 216-218. Date of Electronic Publication: 2019 Nov 13.